Companies marketing pharmaceutical, medical device and diagnostic products may find the best growth opportunities in China’s second tier cities
In a recent report we note that the percentage of Chinese residing in urban healthcare markets rose from 36% to 50% between 2000 and 2010. While major urban healthcare markets – concentrated around metropolises like Shanghai, Hong Kong, Beijing and Guangzhou – have long featured high demand for a range of pharmaceutical and medical devices, pronounced urbanization throughout China has nurtured demand in second-tier cities along China’s coastal provinces, but also in the middle and western half of the country.
“Cities like Chengdu, Chongqing in West China; Zhengzhou and Wuhan in Central China are already the beneficiaries of MNC R&D investment,” said analyst Emil Salazar, “but are also targets for medical product sales and ideal hubs for provincial and regional distribution networks for pharmaceuticals, IVD reagents and other medical supplies.” Among other findings from Kalorama’s report, provinces of Southwestern and Central China are projected to see the greatest market growth for pharmaceuticals and medical devices over the next four year with strong demand out of their emerging regional metropolises.
The full report from Kalorama Information
China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets
includes breakdowns of the IVD, pharmaceutical and medical device market by regions with figures from 2004 to 2015. More information on this report can be found at: http://www.kaloramainformation.com/China-Healthcare-Reform-6609070/